In a biomarker analysis presented at the 2020 SABCS, it was shown that the benefit in favour of SG was maintained independent of the degree of Trop‐2 expression, although numerically the smallest PFS and OS difference was observed in patients with Trop‐2 low-expressing tumours (PFS: Trop‐2 high 6.9 vs. 2.5 months, Trop‐2 medium 5.6 vs. 2.2 months, Trop‐2 low 2.7 vs. 1.6 months; OS: Trop‐2 high 14.2 vs. The gene discussed is TACSTD2; the disease is neoplasm.